Key Highlights

● AJG closed at $232.47 on 9 October 2026, and the $284.50 consensus target implies upside of about 22.4%.

● The consensus draws on 20 analysts, with targets from $260 to $334, while the second data set shows a $284.17 mean from 23 analysts.

● Market data shows 14 Buy and six Hold ratings with no Sell, a Moderate Buy consensus.

● Mizuho cut its target to $271 from $292 and Cantor Fitzgerald to $280 from $300 on 7 October, and Morgan Stanley cut to $260 from $285 on 6 October.

Arthur J. Gallagher & Co. (NYSE:AJG), the insurance broking and risk management group, is part of the S&P 500. The shares closed at $232.47 on Friday 9 October 2026, some 18% below the $284.50 consensus analyst target.

What Is the Latest Analyst Price Target?

Market data shows a consensus price target of $284.50 from 20 analysts over the past 12 months, with a high of $334.00 and a low of $260.00. Compared with the $232.47 close, that implies potential upside of about 22.4%.

The second data set, based on third-party data for 23 analysts, reports a very similar average of $284.17 and a median of $282.50. Its range is wider, from $250 to $388. Both data sets were last updated on 7 October, so they predate the Friday close.

The figures also line up with recent named targets. Nine broker targets published since late July average about $282, so the consensus does not look inflated by outdated forecasts.

What Are Wall Street Analysts Saying?

Ratings are positive but not unanimous. Market data records 14 Buy and six Hold ratings with no Sells, a Moderate Buy consensus. The second data set lists 12 Strong Buy, four Buy and seven Hold ratings, again with no Sells.

The direction of recent target changes has turned lower. On 7 October Mizuho cut its target from $292 to $271 and Cantor Fitzgerald from $300 to $280, while Oppenheimer initiated coverage at Market Perform without a published target. Morgan Stanley reduced its target from $285 to $260 on 6 October. On 24 September Wells Fargo lowered from $296 to $291 and RBC from $310 to $290, and Piper Sandler reiterated an Overweight rating.

Earlier in the summer the tone was more constructive: Argus raised its target from $267 to $300 on 17 August, Citigroup from $250 to $285 on 4 August, UBS from $291 to $299 on 3 August and Truist from $225 to $265 on 31 July.

What Could Help the Stock Reach the Price Target?

Operating performance is the most obvious support. The summary of the latest quarter cites earnings per share of $2.84 against a $2.81 consensus estimate and revenue of $3.95 billion, which it describes as 24.3% higher than a year earlier. Sustained growth at anything like that rate would give analysts room to defend their forecasts.

A stabilisation in target revisions would also help sentiment. With most brokers still rating the shares Buy or equivalent, any evidence that the recent cuts have run their course could narrow the gap between the share price and the consensus target.

What Could Prevent the Stock Reaching the Target?

The recent run of reductions from Mizuho, Cantor Fitzgerald, Morgan Stanley, RBC and Wells Fargo suggests brokers are becoming more cautious. Further cuts would reduce the consensus and the implied upside.

There is also some uncertainty in the data itself. Wolfe Research downgraded the shares to Peer Perform in July, and six or seven analysts currently rate the stock Hold.

What Should Investors Watch Next?

Other items worth following include further analyst revisions, organic growth figures at the next results and any change in sector sentiment towards insurance brokers.

Gallagher's Buy Ratings Hold Firm While Broker Targets Retreat

Gallagher closed at $232.47 on 9 October 2026, with the $284.50 consensus target about 22% higher and the second data set's $284.17 average almost identical. Ratings remain broadly positive, with 14 Buy and six Hold ratings and no Sell, but the direction of recent target changes has turned lower, with Mizuho, Cantor Fitzgerald, Morgan Stanley, RBC and Wells Fargo all cutting since late September. Latest-quarter earnings of $2.84 per share against a $2.81 estimate and revenue 24.3% higher than a year earlier are the operating support for the targets.